Results 31 to 40 of about 1,816 (169)

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C. [PDF]

Int J Hepatol
Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Tawara S, Watanabe A, Yamaguchi J, Omi M, Miyazaki T, Taguchi H, Kiyota R, Yamai T, Kawai S, Inoue T, Yakushijin T.   +10 more
europepmc   +2 more sources

Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. [PDF]

PLoS ONE, 2016
The aim of this study was to evaluate the efficacy of daclatasvir plus asunaprevir therapy in patients infected with hepatitis C virus and determine its relevance to resistant variants.A total of 629 consecutive patients infected with hepatitis C virus ...
Tatsuya Ide, Yuichiro Eguchi, Masaru Harada, Kunihide Ishii, Masaru Morita, Yasuyo Morita, Gen Sugiyama, Hirofumi Fukushima, Yoichi Yano, Kazunori Noguchi, Hiroki Nakamura, Junjiro Hisatomi, Hiroto Kumemura, Miki Shirachi, Shinji Iwane, Michiaki Okada, Yuichi Honma, Teruko Arinaga-Hino, Ichiro Miyajima, Kei Ogata, Reiichiro Kuwahara, Keisuke Amano, Toshihiro Kawaguchi, Ryoko Kuromatsu, Takuji Torimura, DAAs Multicenter Study Group   +25 more
doaj   +1 more source

Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis

Gut and Liver, 2019
Background/Aims We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods : We performed a single-arm, multicenter prospective study.
Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Tae Hee Lee, Ji Woong Jang, Seok Hyun Kim, Sae Hwan Lee, Hong Soo Kim, Ji Hoon Kim, Seok Bae Kim, Soon Young Ko, Do Seon Song   +11 more
doaj   +1 more source

Predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis C virus genotype 1

Терапевтический архив, 2017
Aim. To identify predictors for the high efficiency of short-term interferon-containing antiviral therapy (AVT) using direct-acting antivirals (DAAs) in patients with chronic hepatitis C (CHC) virus (HCV) type 1 (CHC-1). Materials and methods. A total of
K Yu Kokina, A O Bueverov, P O Bogomolov, M V Matsievich   +3 more
doaj   +1 more source

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders

, 2015
BACKGROUND & AIMS: Improved therapies for peginterferon/ribavirin null or partial responders are needed. This study evaluated daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor) plus peginterferon alfa-2a and ribavirin in this ...
BRUNETTO, MAURIZIA ROSSANA, Everson, G, Kugelmas, M, Pol, S, Jensen, D., Vierling, J, Zeuzem, S, Serfaty, L, de Ledinghen, V, Elkhashab, M, Younes, Zh, Hézode, C, Hennicken, D, Bernstein, D, Sherman, Ke, Luketic, V, Mauss, S, Heo, J, Mcphee, F, Tran, A   +19 more
core   +2 more sources

Eradication of hepatitits C virus in patient with cryoglobulinemic vasculitis and mutations D168E, L31V

Журнал инфектологии, 2020
The case of chronic hepatitis C 1b genotype with grade 3 fibrosis according to Metavir, complicated by the development  of mixed  type  III  cryoglobulinemia,  cryoglobulinemic vasculitis with damage to the skin vessels of the skin (hemorrhagic ...
N. V. Dunaeva, M. A. Chirskaya, E. Yu. Kolpashchikova, S. Yu. Romanova, S. V. Lapin, V. E. Karev, D. A. Gusev   +6 more
doaj   +1 more source

Asunaprevir-containing regimens for the treatment of hepatitis C virus infection

, 2017
Chronic hepatitis C virus (HCV) infection has been a tremendous health burden worldwide with an annual mortality of 300,000 people due to decompensated cirrhosis or hepatocellular carcinoma.
Yang, Sheng-Shun;Kao, Jia-Horng, 高嘉宏   +1 more
core   +1 more source

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018
Introduction. The options of antiviral therapy (AVT) in the stages of severe liver fibrosis and cirrhosis (LC) as well as in the patients with comorbidities for the long time were limited to the standard therapy by pegilated interferon (peg-IFN) in ...
V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina   +13 more
doaj   +1 more source

Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. [PDF]

PLoS Computational Biology, 2015
Recent discoveries of direct acting antivirals against Hepatitis C virus (HCV) have raised hopes of effective treatment via combination therapies.
Ruian Ke, Claude Loverdo, Hangfei Qi, Ren Sun, James O Lloyd-Smith   +4 more
doaj   +1 more source

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C

, 2014
International audienceBackground & AimsAsunaprevir is a selective HCV NS3 protease inhibitor, active against genotypes 1, 4, 5, and 6 in vitro. We evaluated asunaprevir plus peginterferon alfa-2a/ribavirin (PegIFNα/RBV) for genotype 1 and 4 chronic HCV ...
Cohen, David, Hughes, Eric, Ratziu, Vlad, Bessone, Fernando, Mendez, Patricia, Younes, Ziad, Bronowicki, Jean-Pierre, Thuluvath, Paul, Martorell, Claudia, Terg, Ruben, He, Bing, Pol, Stanislas, Hernandez, Dennis, Mcphee, Fiona, Eley, Timothy, Yu, Fei, Gadano, Adrian   +16 more
core   +1 more source